Cyclovirobuxine D

Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR. Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis. Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction.

Product information

CAS Number: 860-79-7

Molecular Weight: 402.66

Formula: C26H46N2O

Chemical Name: (1S, 3R, 6S, 8R, 11S, 12S, 14R, 15S, 16R)-7, 7, 12, 16-tetramethyl-6-(methylamino)-15-[(1S)-1-(methylamino)ethyl]pentacyclo[9.7.0.0, .0, .0, ]octadecan-14-ol

Smiles: CC1(C)[C@@H]2CC[C@@H]3[C@@]4(C[C@@]42CC[C@@H]1NC)CC[C@]1(C)[C@H]([C@H](O)C[C@]13C)[C@H](C)NC

InChiKey: GMNAPBAUIVITMI-ABNIRSKTSA-N

InChi: InChI=1S/C26H46N2O/c1-16(27-6)21-17(29)14-24(5)19-9-8-18-22(2,3)20(28-7)10-11-25(18)15-26(19,25)13-12-23(21,24)4/h16-21,27-29H,8-15H2,1-7H3/t16-,17+,18-,19-,20-,21-,23+,24-,25+,26-/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Ethanol : 13 mg/mL (32.29 mM; Need ultrasonic)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Cyclovirobuxine D (0-240 µM ;24-72 hours) shows a concentration- and time-dependent reduced cell viability after CVB-D treatment, only 10% MGC-803 cells and 20% MKN28 cells are alive at 72 h after treatment with 240 µM. Cyclovirobuxine D (0-120 µM; 48 hours) arrests the cell cycle of gastric cancer cells at S phase in a concentration-dependent manner. Cyclovirobuxine D (0-120 µM; 48 hours) leads to apoptosis in gastric cancer cells in a concentration-dependent manner, especially early stage apoptosis. Cyclovirobuxine D (0-120 µM; 48 hours) causes apoptosis via up-regulation of the apoptosis- related proteins, cleaved Caspase-3 and ratio of Bax/Bcl-2, in gastric cancer cells.

References:

1. Lu J, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol Sci. 2014;125(1):74-82. Epub 2014 Apr 24.
2. Wu J, et al. Cyclovirobuxine D Inhibits Cell Proliferation and Induces Mitochondria-Mediated Apoptosis in Human Gastric Cancer Cells. Molecules. 2015 Nov 19;20(11):20659-68.
3. Yu B, et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction. Fitoterapia. 2011 Sep;82(6):868-77.

Products are for research use only. Not for human use.